Arterial
Remodeling Technologies (“ART”) announced today that it
has disclosed impressive in vivo and in vitro data related
to its bioresorbable stent platform—data that validates the Company’s
approach to simultaneously balance biocompatibility, biomechanics
and bioresorption in a bioresorbable PLA (polylactic acid) stent
without altering healing by drug elution from the stent platform.
“These results dramatically confirm our approach to bioresorbable
stenting”
These data have been published in the current special supplement of EuroIntervention,
a peer-reviewed journal. The paper is authored by Antoine Lafont,
M.D., Ph.D., Head, Interventional Cardiology Department, Georges
Pompidou Hospital (Paris); Past Chairman, Interventional Cardiology
Group, European Society of Cardiology (ESC).
“The ART bioresorbable stent showed a remarkable ability to be deployed
without recoil or breakage. At one month, endothelialization was one
hundred percent completed. Additionally important, inflammation, smooth
muscle cell proliferation and collagen accumulation were equivalent to
what typically occurs after balloon angioplasty,” said Dr. Lafont, a
co-founder of ART. “At six months, the ART stent was completely
integrated into the artery wall, thus preventing any strut migration
secondary to the bioresorption process. Further, peak PLA resorption did
not result in an increase or even persistence of inflammation as it has
been previously reported with other bioresorbable polymer stents.
Finally, inflammation and smooth muscle cell proliferation were almost
not detectable at six months, resulting in no hyperplasia—in other
words, no in-stent restenosis.”